메뉴 건너뛰기




Volumn 46, Issue SUPPL. 2, 2008, Pages

Business considerations in the development of probiotics

Author keywords

[No Author keywords available]

Indexed keywords

COSMETIC; PROBIOTIC AGENT;

EID: 40049085564     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/523323     Document Type: Conference Paper
Times cited : (5)

References (13)
  • 1
    • 40049111167 scopus 로고    scopus 로고
    • Dietary Supplement Health and Education Act of 1994 [Public Law 103-417] [amended the FD & C Act, Section 411(c)(1)(B) (21 USC 350(c)(1)(B))].
    • Dietary Supplement Health and Education Act of 1994 [Public Law 103-417] [amended the FD & C Act, Section 411(c)(1)(B) (21 USC 350(c)(1)(B))].
  • 2
    • 40049086322 scopus 로고    scopus 로고
    • US Food and Drug Administration. 21 CFR Parts 170, et al. Proposed rules: substances generally recognized as safe; proposed rule. Fed Reg 1997; 62:18937-64.
    • US Food and Drug Administration. 21 CFR Parts 170, et al. Proposed rules: substances generally recognized as safe; proposed rule. Fed Reg 1997; 62:18937-64.
  • 3
    • 40049091900 scopus 로고    scopus 로고
    • 21 CFR §190.6(b)(4).
    • 21 CFR §190.6(b)(4).
  • 4
    • 40049097485 scopus 로고    scopus 로고
    • 21 CFR §170.20
    • 21 CFR §170.20.
  • 5
    • 0037160569 scopus 로고    scopus 로고
    • US Food and Drug Administration. 21 CFR Part 330, et al. Final rule: additional criteria and procedures for classifying over-the-counter drugs as generally recognized as safe and effective and not misbranded. Fed Reg 2002; 67:3060-76.
    • US Food and Drug Administration. 21 CFR Part 330, et al. Final rule: additional criteria and procedures for classifying over-the-counter drugs as generally recognized as safe and effective and not misbranded. Fed Reg 2002; 67:3060-76.
  • 9
    • 40049085707 scopus 로고    scopus 로고
    • Public Health Service Act [42 USC §262(i)].
    • Public Health Service Act [42 USC §262(i)].
  • 10
    • 40049099655 scopus 로고    scopus 로고
    • 21 CFR §314.126
    • 21 CFR §314.126.
  • 11
    • 40049110871 scopus 로고    scopus 로고
    • Drug Price Competition and Patent Term Restoration Act of 1984
    • Drug Price Competition and Patent Term Restoration Act of 1984.
  • 12
    • 40049094298 scopus 로고    scopus 로고
    • Public Health Service Act [42 USC §262(j)].
    • Public Health Service Act [42 USC §262(j)].
  • 13
    • 40049085065 scopus 로고    scopus 로고
    • US Food and Drug Administration, Center for Biologics Evaluation and Research. Product approval information - licensing action. FDA letter to Organon Teknika Corporation, regarding a Supplement to license application 92-0306 for BCG Live (TICE BCG). 21 August 1998. Available at: http://www.fda.gov. Accessed 17 December 2007.
    • US Food and Drug Administration, Center for Biologics Evaluation and Research. Product approval information - licensing action. FDA letter to Organon Teknika Corporation, regarding a Supplement to license application 92-0306 for BCG Live (TICE BCG). 21 August 1998. Available at: http://www.fda.gov. Accessed 17 December 2007.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.